Therapeutic Candidate or Device pancreatic progenitor cells in a delivery device that allows direct vascularization Indication high-risk type 1 diabetes including "brittle" diabetes and hypoglycemia unawareness Therapeutic Mechanism People with…
Therapeutic Candidate or Device hESC-derived pancreatic progenitor cells delivered in a device that allows direct vascularization of the cell therapy Indication high-risk type 1 diabetes including "brittle" diabetes and hypoglycemia…
California's Stem Cell Agency (CIRM) hosted a live Google Hangout about recent progress in stem cell based strategies for diabetes therapies. The speakers included: Francisco Prieto, MD - CIRM's…
CIRM has funded the Diabetes Disease Team led by scientists at ViaCyte, Inc., UCSF, and the La Jolla Institute for Allergy and Immunology. This team aims to bring an embryonic…
Eugene Brandon speaks at the 2011 CIRM Grantee Meeting about Viacyte's efforts to develop a stem cell based treatment for diabetes. CIRM has awarded Viacyte $26 million to support their…
Embryonic stem cells have the potential to help treat 70 or more diseases, but developing those new therapies will take time. Alan Lewis is the former president and CEO of…
Robert Klein, J.D. gave the welcoming remarks for the "Spotlight on Juvenile Diabetes", an educational event presented at the CIRM Governing Board meeting on September 25, 2008. Klein is Chair…
Ed Baetge, Ph.D. spoke at the Spotlight on Juvenile Diabetes, an educational event presented at the CIRM Governing Board meeting on September 25, 2008. Baetge discussed Novocell, Inc.'s (now…
Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
